210 related articles for article (PubMed ID: 30886380)
1. The WNT/β-catenin signaling inhibitor XAV939 enhances the elimination of LNCaP and PC-3 prostate cancer cells by prostate cancer patient lymphocytes in vitro.
Stakheev D; Taborska P; Strizova Z; Podrazil M; Bartunkova J; Smrz D
Sci Rep; 2019 Mar; 9(1):4761. PubMed ID: 30886380
[TBL] [Abstract][Full Text] [Related]
2. Role of Wnt/beta-catenin signaling pathway in epithelial-mesenchymal transition of human prostate cancer induced by hypoxia-inducible factor-1alpha.
Jiang YG; Luo Y; He DL; Li X; Zhang LL; Peng T; Li MC; Lin YH
Int J Urol; 2007 Nov; 14(11):1034-9. PubMed ID: 17956532
[TBL] [Abstract][Full Text] [Related]
3. Tankyrase inhibitors attenuate WNT/β-catenin signaling and inhibit growth of hepatocellular carcinoma cells.
Ma L; Wang X; Jia T; Wei W; Chua MS; So S
Oncotarget; 2015 Sep; 6(28):25390-401. PubMed ID: 26246473
[TBL] [Abstract][Full Text] [Related]
4. Suppression of Wnt/beta-catenin signaling inhibits prostate cancer cell proliferation.
Lu W; Tinsley HN; Keeton A; Qu Z; Piazza GA; Li Y
Eur J Pharmacol; 2009 Jan; 602(1):8-14. PubMed ID: 19026633
[TBL] [Abstract][Full Text] [Related]
5. Inhibition of Wnt/β-catenin signaling mediates ursolic acid-induced apoptosis in PC-3 prostate cancer cells.
Park JH; Kwon HY; Sohn EJ; Kim KA; Kim B; Jeong SJ; Song JH; Koo JS; Kim SH
Pharmacol Rep; 2013; 65(5):1366-74. PubMed ID: 24399733
[TBL] [Abstract][Full Text] [Related]
6. Tankyrase 1 inhibitior XAV939 increases chemosensitivity in colon cancer cell lines via inhibition of the Wnt signaling pathway.
Wu X; Luo F; Li J; Zhong X; Liu K
Int J Oncol; 2016 Apr; 48(4):1333-40. PubMed ID: 26820603
[TBL] [Abstract][Full Text] [Related]
7. Inhibition of Wnt/β-catenin signaling promotes epithelial differentiation of mesenchymal stem cells and repairs bleomycin-induced lung injury.
Wang C; Zhu H; Sun Z; Xiang Z; Ge Y; Ni C; Luo Z; Qian W; Han X
Am J Physiol Cell Physiol; 2014 Aug; 307(3):C234-44. PubMed ID: 24898581
[TBL] [Abstract][Full Text] [Related]
8. Wnt/beta-catenin pathway: modulating anticancer immune response.
Pai SG; Carneiro BA; Mota JM; Costa R; Leite CA; Barroso-Sousa R; Kaplan JB; Chae YK; Giles FJ
J Hematol Oncol; 2017 May; 10(1):101. PubMed ID: 28476164
[TBL] [Abstract][Full Text] [Related]
9. Inhibiting Wnt/beta-catenin in CTNNB1-mutated endometrial cancer.
Moroney MR; Woodruff E; Qamar L; Bradford AP; Wolsky R; Bitler BG; Corr BR
Mol Carcinog; 2021 Aug; 60(8):511-523. PubMed ID: 34038589
[TBL] [Abstract][Full Text] [Related]
10. Cotargeting Polo-Like Kinase 1 and the Wnt/β-Catenin Signaling Pathway in Castration-Resistant Prostate Cancer.
Li J; Karki A; Hodges KB; Ahmad N; Zoubeidi A; Strebhardt K; Ratliff TL; Konieczny SF; Liu X
Mol Cell Biol; 2015 Dec; 35(24):4185-98. PubMed ID: 26438599
[TBL] [Abstract][Full Text] [Related]
11. Inhibition of canonical WNT signaling attenuates human leiomyoma cell growth.
Ono M; Yin P; Navarro A; Moravek MB; Coon V JS; Druschitz SA; Gottardi CJ; Bulun SE
Fertil Steril; 2014 May; 101(5):1441-9. PubMed ID: 24534281
[TBL] [Abstract][Full Text] [Related]
12. Next-generation sequencing of advanced prostate cancer treated with androgen-deprivation therapy.
Rajan P; Sudbery IM; Villasevil ME; Mui E; Fleming J; Davis M; Ahmad I; Edwards J; Sansom OJ; Sims D; Ponting CP; Heger A; McMenemin RM; Pedley ID; Leung HY
Eur Urol; 2014 Jul; 66(1):32-9. PubMed ID: 24054872
[TBL] [Abstract][Full Text] [Related]
13. XAV939, a Wnt/β-catenin pathway modulator, has inhibitory effects on LPS-induced inflammatory response.
Jang J; Jung Y; Chae S; Bae T; Kim SM; Shim YJ; Chung SI; Yoon Y
Immunopharmacol Immunotoxicol; 2019 Jun; 41(3):394-402. PubMed ID: 30466341
[No Abstract] [Full Text] [Related]
14. Capsaicin suppressed activity of prostate cancer stem cells by inhibition of Wnt/β-catenin pathway.
Zhu M; Yu X; Zheng Z; Huang J; Yang X; Shi H
Phytother Res; 2020 Apr; 34(4):817-824. PubMed ID: 31782192
[TBL] [Abstract][Full Text] [Related]
15. Salinomycin suppresses LRP6 expression and inhibits both Wnt/β-catenin and mTORC1 signaling in breast and prostate cancer cells.
Lu W; Li Y
J Cell Biochem; 2014 Oct; 115(10):1799-807. PubMed ID: 24905570
[TBL] [Abstract][Full Text] [Related]
16. Inhibition of WNT signaling reduces differentiation and induces sensitivity to doxorubicin in human malignant neuroblastoma SH-SY5Y cells.
Suebsoonthron J; Jaroonwitchawan T; Yamabhai M; Noisa P
Anticancer Drugs; 2017 Jun; 28(5):469-479. PubMed ID: 28240680
[TBL] [Abstract][Full Text] [Related]
17. Critical role of Wnt/β-catenin signaling in driving epithelial ovarian cancer platinum resistance.
Nagaraj AB; Joseph P; Kovalenko O; Singh S; Armstrong A; Redline R; Resnick K; Zanotti K; Waggoner S; DiFeo A
Oncotarget; 2015 Sep; 6(27):23720-34. PubMed ID: 26125441
[TBL] [Abstract][Full Text] [Related]
18. mTOR signaling mediates resistance to tankyrase inhibitors in Wnt-driven colorectal cancer.
Mashima T; Taneda Y; Jang MK; Mizutani A; Muramatsu Y; Yoshida H; Sato A; Tanaka N; Sugimoto Y; Seimiya H
Oncotarget; 2017 Jul; 8(29):47902-47915. PubMed ID: 28615517
[TBL] [Abstract][Full Text] [Related]
19. Tumor-suppressive microRNA-145 targets catenin δ-1 to regulate Wnt/β-catenin signaling in human colon cancer cells.
Yamada N; Noguchi S; Mori T; Naoe T; Maruo K; Akao Y
Cancer Lett; 2013 Jul; 335(2):332-42. PubMed ID: 23499891
[TBL] [Abstract][Full Text] [Related]
20. Small molecule antagonists of the Wnt/β-catenin signaling pathway target breast tumor-initiating cells in a Her2/Neu mouse model of breast cancer.
Hallett RM; Kondratyev MK; Giacomelli AO; Nixon AM; Girgis-Gabardo A; Ilieva D; Hassell JA
PLoS One; 2012; 7(3):e33976. PubMed ID: 22470504
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
